{"title":"Hydroxychloroquine for COVID-19: Variation in Regional Political Preferences Predicted New Prescriptions after President Trump's Endorsement.","authors":"Farrah Madanay, Ryan C McDevitt, Peter A Ubel","doi":"10.1215/03616878-9716698","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>On March 19, 2020, President Donald Trump endorsed using hydroxychloroquine for COVID-19 treatment despite inconclusive evidence of the drug's effectiveness. This study sought to understand the influence of political preferences on prescription uptake by quantifying the relationship between a geographic area's partisan leaning and hydroxychloroquine prescription rates following Trump's endorsement.</p><p><strong>Methods: </strong>We analyzed hydroxychloroquine prescriptions filled in 205 continental US designated market areas (DMAs) between March 1, 2018, and July 31, 2020, and the percentage of votes for Donald Trump in the 2016 presidential election in each DMA. We estimated associations by using an empirical strategy resembling a difference-in-differences estimation.</p><p><strong>Findings: </strong>Before President Trump's endorsement, mean weekly hydroxychloroquine prescription rates were similar across DMAs with the highest and lowest Trump vote percentages (0.56 and 0.49 scripts per 100,000). After Trump's endorsement, although both high- and low-Trump-supportive DMAs experienced sharp increases in weekly hydroxychloroquine prescription rates, results indicated a 1-percentage-point increase in share of Trump votes was associated with 0.013, or 2%, more weekly hydroxychloroquine prescriptions per 100,000 people (b = 0.013, t = 2.20, p = .028).</p><p><strong>Conclusion: </strong>President Trump's endorsement of an untested therapy influenced prescribing behavior, especially when that endorsement aligned with communities' political leanings.</p>","PeriodicalId":3,"journal":{"name":"ACS Applied Electronic Materials","volume":null,"pages":null},"PeriodicalIF":4.3000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Electronic Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1215/03616878-9716698","RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENGINEERING, ELECTRICAL & ELECTRONIC","Score":null,"Total":0}
引用次数: 3
Abstract
Context: On March 19, 2020, President Donald Trump endorsed using hydroxychloroquine for COVID-19 treatment despite inconclusive evidence of the drug's effectiveness. This study sought to understand the influence of political preferences on prescription uptake by quantifying the relationship between a geographic area's partisan leaning and hydroxychloroquine prescription rates following Trump's endorsement.
Methods: We analyzed hydroxychloroquine prescriptions filled in 205 continental US designated market areas (DMAs) between March 1, 2018, and July 31, 2020, and the percentage of votes for Donald Trump in the 2016 presidential election in each DMA. We estimated associations by using an empirical strategy resembling a difference-in-differences estimation.
Findings: Before President Trump's endorsement, mean weekly hydroxychloroquine prescription rates were similar across DMAs with the highest and lowest Trump vote percentages (0.56 and 0.49 scripts per 100,000). After Trump's endorsement, although both high- and low-Trump-supportive DMAs experienced sharp increases in weekly hydroxychloroquine prescription rates, results indicated a 1-percentage-point increase in share of Trump votes was associated with 0.013, or 2%, more weekly hydroxychloroquine prescriptions per 100,000 people (b = 0.013, t = 2.20, p = .028).
Conclusion: President Trump's endorsement of an untested therapy influenced prescribing behavior, especially when that endorsement aligned with communities' political leanings.
背景:2020年3月19日，唐纳德·特朗普总统批准使用羟氯喹治疗COVID-19，尽管没有确凿的证据表明这种药物的有效性。本研究试图通过量化地理区域的党派倾向与特朗普支持后羟氯喹处方率之间的关系，了解政治偏好对处方摄取的影响。方法:我们分析了2018年3月1日至2020年7月31日期间美国205个大陆指定市场区域(DMA)的羟氯喹处方，以及唐纳德·特朗普在2016年总统大选中的得票率。我们通过使用一种类似于差中差估计的经验策略来估计关联。研究结果:在特朗普总统的支持之前，特朗普投票百分比最高和最低的dma的平均每周羟氯喹处方率相似(每10万人中0.56和0.49个处方)。在特朗普的支持之后，尽管高支持特朗普和低支持特朗普的dma每周羟氯喹处方率都急剧上升，但结果表明，特朗普的选票份额每增加1个百分点，每周羟氯喹处方率就会增加0.013，即每10万人增加2% (b = 0.013, t = 2.20, p = 0.028)。结论:特朗普总统对一种未经测试的疗法的认可影响了处方行为，尤其是当这种认可与社区的政治倾向相一致时。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
